Outlook Therapeutics

OTLKNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$190.737 M

$1.02 +4.88%

Close of 7 Aug 2026

Revenue

$1.41M

#3470 by revenue

Earnings

-$62.4M

Loss-making

Shares outstanding

120,863,252

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#98Coherus OncologyCHRS$196.2M
#99Precision BiosciencesDTIL$193.3M
#100Outlook TherapeuticsOTLK$190.7M
#101Acumen PharmaceuticalsABOS$176.2M
#102Armata PharmaceuticalsARMP$172.9M

Where these numbers come from

Share counts and financials for Outlook Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.